Enveda
What they do
Enveda is revolutionizing drug discovery by tapping into the vast potential of life’s chemical diversity. Using its AI-driven search engine, the company decodes and maps the complex chemistry found in living systems, unlocking an untapped dark chemical space and discovering novel drug candidates.
Founded by molecular biologist Viswa Colluru – formerly of Recursion, another Kinnevik company – Enveda was built on the belief that nature holds answers to many diseases. Though some of the most successful drugs in human history came from plants, nature-inspired drug discovery declined because of the slow, inefficient and difficult process of interpreting plant chemistry. Enveda overcomes this through its proprietary platform built around mass spectrometry, machine learning and advanced robotics.
In the four years since its seed round, Enveda’s platform has generated 16 preclinical programs, over 10 development candidates, five assets in IND (Investigational New Drug)-enabling studies, and one candidate that entered the clinic in Q4 2024 with a successful Phase 1a trial. Over the next 1-2 years, Enveda is dedicated to advancing key programs to critical value-inflection milestones, partnering select programs to unlock near-term value through strategic business development.
Why Kinnevik is invested
Kinnevik is attracted by Enveda’s innovative approach to drug discovery and its potential to redefine health. By combining novel AI with deep scientific expertise, Enveda addresses longstanding challenges in uncovering effective treatments, positioning itself as a highly promising player in the sector.
Key information
- Clinical-stage biotech pioneering small molecule drug discovery inspired from life’s chemistry
- Leverages mass spectrometry, robotics and advanced machine-learning techniques to map life’s chemistry and uncover novel therapeutics
- Focused on advancing novel drugs to critical value-inflection milestones through internal development, retaining optionality of partnering out selective programs
News in the quarter
- Enveda’s leading drug candidate successfully completed Phase 1a clinical trials, validating the company’s AI-driven drug discovery platform. A Phase 1b clinical trial is set to launch in the second half of 2025, evaluating the candidate in patients with eczema
- Featured in “The Next Frontier”, a global series presented by the Biotechnology Innovation Organization and BBC StoryWorks, showcasing the chemistry found in nature as one of the most powerful yet unexplored sources of medicine
